期刊文献+

胺碘酮和心律平治疗心力衰竭并室性心律失常的对比观察 被引量:4

Analysis effect of amiodarone,and propafenone on patients with heart failure and ventricular arrhythmia
下载PDF
导出
摘要 目的 分析对比观察胺碘酮、心律平治疗充血性心力衰竭合并室性心律失常的临床疗效与安全性.方法 80例充血性心力衰竭合并室性心律失常的患者分成两组,每组各40例.两组患者抗心力衰竭治疗相同,观察组应用胺碘酮抗心律失常,对照组应用心律平抗心律失常,疗程4周,观察临床疗效、室性心律失常及左心室射血分数(LVEF)的变化,并对结果进行回顾性分析.结果 治疗后观察组临床疗效高于对照组(P<0.01),室性心律失常减少高于对照组(P<0.05),LVEF值增加优于对照组(P<0.05).对照组有6例出现新的心律失常,停用心律平后恢复.结论 充血性心力衰竭合并室性心律失常必须长期使用抗心律失常药物时,应首选胺碘酮治疗而不宜使用心律平. Objective To compare and observe effect and safety of arniodarone, and propafenone on patients with heart failure and ventricular arrhythmia. Methods 80 patients with heart failure and ventricular arrhythmia were divided into two groups, each 40 respectively. Both groups with same anti-heart failure therapy, administrating amiodarone in the therapy group, propafenone in the control group, and reviewing analysis effect observe clinic effect, ventricular arrhythmia, left ventrieular ejection fraction. Results Clinic effect of therapy group was better than that of control group (P〈0.01), ventrieular arrhythmia in therapy group decreased than con- trol group (P〈0.05), LVEF increased than control group (P〈0.05). And 6 patients in control group showed new cardiac arrhythmia and recovered when discontinuing propafenone. Conclusion When patients with heart failure and ventrieular arrhythmia must administrate anti-arrhythmia medications, amiodarone should be chosen rather than propafenone.
出处 《中国心血管病研究》 CAS 2011年第3期210-212,共3页 Chinese Journal of Cardiovascular Research
关键词 心力衰竭 心律失常 胺碘酮 心律平 Heart failure heart Cardiac arrhythmia Amiodarone Propafenone
  • 相关文献

参考文献9

二级参考文献12

  • 1张亚文,吴宗贵,李莉.胺碘酮和普罗帕酮治疗冠心病并室性心律失常的疗效比较[J].中国心脏起搏与心电生理杂志,2004,18(5):344-346. 被引量:15
  • 2任自文.胺碘酮的肺毒性六例报告[J].中华心血管病杂志,2005,33(1):66-68. 被引量:10
  • 3蒋文平.胺碘酮抗心律失常治疗应用指南[J].中华心血管病杂志,2004,32(12):1065-1071. 被引量:142
  • 4杨淑芳,秦俭,王晶,孙长怡,李亚林,曹涛,李俊芬.急诊应用胺碘酮治疗快速心律失常的疗效和安全性[J].中国急救医学,2005,25(3):218-219. 被引量:35
  • 5[1]Landers MD, Reifer MJ.General principles of antiarrhythic therapy for ventricular tacharrhythmias. Am J Cardiol,1997,80: 31-33.
  • 6[2]Lazzara R.From first class to third class:Recent upheaval in antiarrhythictherapy-lessons from clinical trial. Am J Cardiol, 1996,78(Suppl 1): S28-S31.
  • 7[3]SirIsh BN.The coming of age of the class Ⅲ antiarrhythic principle.Am J Cardiol, 1996,78(Suppl 1): S17-S19.
  • 8[1]Lazzara R.Fromfirst classtothird class:recent upheaval in antiarrhythictherapy-lessons from clinical trial.Am J Cardiol,1996,78(Suppl):S28.
  • 9[4]Singh BN.The coming of age of the class Ⅲ antiarrhythic principle.Am J Cardiol,1996,78(Suppl):S17.
  • 10[5]Cairns JA,Connolly SJ,Roberts RS,et al.Randomized trial of outcome after myocardial infarction with frequent or repetitive Ventrienlar premature depolarization CAMIT.Lancel,1999,353:93-105.

共引文献15

同被引文献27

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部